Therefore, pharmacological approaches aimed at modulating GDF15 levels or its signaling pathway could provide new treatment strategies against conditions with dysregulated sympathetic activity including obesity, hypertension or idiopathic orthostatic hypotension. Here, GDF15 is linked to obesity due to melanocortin 4 receptor deficiency.